Shingrix gives GSK a near-term boost

Questions on future growth still loom large, however, amid a pipeline revamp and competitive pressures in the pharma's core therapeutic areas.

By Ned Pagliarulo • Nov. 1, 2018

Novartis wins US nod for Humira biosimilar, but focus now on Europe

A settlement deal blocks market launch in the U.S. until 2023. In Europe, however, the battle for market share is just beginning. 

By Ned Pagliarulo • Oct. 31, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Come January, will pharma pricing pledges hold?

Pfizer CEO Ian Read indicated this week that the pharma, which rolled back some price hikes in July, would return to "business as normal" next year. 

By Ned Pagliarulo • Oct. 31, 2018

Red pill or blue? It could be a billion-dollar decision

Viagra and Nexium ​underscore how marketers and manufacturers can use color to make a drug franchise more successful.

By Jacob Bell • Oct. 29, 2018

Amgen, Regeneron appear most at risk from Trump's latest pricing plan

Pharma hates the proposal to link Medicare Part B payments to international prices. But some drugmakers would stand to lose more than others.

By Ned Pagliarulo • Oct. 26, 2018

Trump pitches new plan to bring US drug prices down

The administration's latest effort will take aim at Medicare Part B, aiming to link drug payments in the U.S. to the prices pharmaceutical companies set abroad. 

By Ned Pagliarulo , David Lim • Updated Oct. 25, 2018

FDA approves flu drug with new mechanism of action

Just in time for the flu season, the newly OK'd antiviral treatment could be the viral boost that Roche needs.

By Suzanne Elvidge • Oct. 25, 2018

Amgen cuts US Repatha price 60% amid market pressure

While effective, the cholesterol drug's $14,520 list price has been a tough pill to swallow for payers. Now, Amgen will cut the price to $5,850.

By Ned Pagliarulo , Jacob Bell • Updated Oct. 24, 2018

DTC's big issues: Trump, cancer drugs and the First Amendment

Direct-to-consumer drug advertising, while always controversial, looks set to become a battleground yet again.

By Ned Pagliarulo , Jacob Bell , Andrew Dunn • Oct. 24, 2018

Reimbursement lags cancer drug approvals, but some European countries wait longer

While approvals of new drugs are centralized in the EU, decisions on reimbursement falls to individual countries — with varying results.

By Ned Pagliarulo • Oct. 24, 2018

Advair copy approval 'imminent,' Mylan says, but investors jittery

An FDA decision was expected in mid-October after the company was hit with a CRL in June. Hundreds of millions of dollars could be on the line.

By Ned Pagliarulo • Oct. 23, 2018

Biogen talks threats to Spinraza, but mum on BAN2401

The spinal muscular atrophy drug was the big biotech's main growth driver in the quarter. Yet attention remains on Alzheimer's data due Thursday.

By Jacob Bell • Oct. 23, 2018

Viagra no more: The changing face of drug ads on TV

Gone are twin bathtubs and little blue pills. Instead, pharma promotions on TV are more likely to feature complex biologics and cancer drugs. 

By Ned Pagliarulo • Oct. 22, 2018

First Amendment takes center stage in DTC price fight

A string of court decisions have bolstered commercial speech rights for industry. The Trump administration's push to require prices in TV ads could become the next legal battleground.

By Andrew Dunn • Oct. 22, 2018

FDA unconvinced by Novartis pitch for canakinumab

The agency knocked back an application for approval of the drug, already on the market as Ilaris, as a treatment for cardiovascular risk reduction. 

By Jacob Bell • Oct. 19, 2018

AbbVie reaches 5th deal to secure Humira through 2023

Through a settlement with AbbVie, Fresenius Kabi's copycat biologic won't launch in the U.S. until late 2023, pending it securing FDA approval by then. 

By Suzanne Elvidge • Oct. 19, 2018

Amgen launches TV spot for Aimovig in tight CGRP market

The campaign comes days after the Trump administration proposed mandating disclosure of list prices in prescription drug ads.

By Andrew Dunn • Oct. 17, 2018

Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

A lawsuit filed Tuesday claims that, rather than protect patient access, the companies jacked up insulin prices in order to offer greater rebates to PBMs.

By Jacob Bell • Oct. 17, 2018

Humira biosimilars launch in Europe, testing AbbVie

Copycat biologics of Humira launched on Oct. 16, exposing the world's best-selling drug to competition for the first time since its EU approval in 2003.

By Ned Pagliarulo • Updated Oct. 19, 2018

Amgen, Lilly migraine drugs make it onto Express Scripts' preferred list

The decision boosts Aimovig and Emgality in the competitive CGRP space, while dealing a blow to Teva's rival therapy, Ajovy.

By Jacob Bell • Oct. 17, 2018

Biosimilars bite into Herceptin in Europe

Yet Roche sustained growth thanks to fast uptake of new drugs like Ocrevus. Next year could prove a tougher test, when biosimilars enter in the U.S.

By Ned Pagliarulo • Oct. 17, 2018

An early approval puts Pfizer's Talzenna in a crowded field

Pfizer picked up the PARP inhibitor in its $14 billion deal for Medivation two years ago. Talzenna will join three other drugs on market that work similarly.

By Suzanne Elvidge • Oct. 17, 2018

Engage your HCP audiences through strategic use of digital networks: What's working today

Pharma companies should consider distributing their marketing message through HCP channels.

By Catherine Dold, BioPharma Dive Contributing Editor • Oct. 16, 2018

J&J sees 'evolution in pricing, not a revolution' in 2019

"I think we just need to be careful; things such as list price alone [are] not the full extent of the information," said J&J's pharma unit chief on a Tuesday call.

By Jacob Bell • Oct. 16, 2018

5 questions on the Trump admin's bid to mandate prices in drug ads

Pharma, which spends billions each year to advertise its products on television, is expected to fiercely oppose the proposal.

By Ned Pagliarulo , Andrew Dunn • Oct. 16, 2018